Akademska digitalna zbirka SLovenije - logo
E-viri
Recenzirano Odprti dostop
  • Novel activating mutations ...
    Shochat, Chen; Tal, Noa; Gryshkova, Vitalina; Birger, Yehudit; Bandapalli, Obul R.; Cazzaniga, Giovanni; Gershman, Nava; Kulozik, Andreas E.; Biondi, Andrea; Mansour, Marc R.; Twizere, Jean-Claude; Muckenthaler, Martina U.; Ben-Tal, Nir; Constantinescu, Stefan N.; Bercovich, Dani; Izraeli, Shai

    Blood, 07/2014, Letnik: 124, Številka: 1
    Journal Article, Web Resource

    Gain-of-function somatic mutations introducing cysteines to either the extracellular or to the transmembrane domain (TMD) in interleukin-7 receptor α (IL7R) or cytokine receptor-like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD closer to the cytosolic domain. Biochemical and functional assays showed that these are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells in vitro and are transforming in vivo. Protein fragment complementation assays suggest that despite the absence of cysteines, the mechanism of activation is through ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations suggest that the mutations stabilize the homodimeric conformation, positioning the cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous receptor activation independently of external signals. Hence, type I cytokine receptors may be activated in leukemia through 2 types of transmembrane somatic dimerizing mutations. •Two distinct regions of transmembrane somatic mutations in type I cytokine receptors IL7R and CRLF2 exist in acute lymphoblastic leukemias.•Noncysteine transmembrane mutations cause functional receptor dimerization and activation transforming pro-B cells.